It wasn’t long ago that investors couldn’t run away from Western Digital (WDC) fast enough. The darling of contrarian tech investors only two years ago as its share price soared above $100, rapidly declining sales of PCs during the past year and concerns over the price Western Digital paid to… Read More
Jim Pearce is the Chief Investment Strategist of Personal Finance, our flagship publication, and manages two trading services, PF Pro and Mayhem Trader. He began his career as a stockbroker in 1983 and over the years has managed client investment portfolios for major banks, brokerage firms, and investment advisors. Jim earned a BA from The College of William & Mary and the CFP designation from the College of Financial Planning.
Analyst Articles
If you like to profit from mergers and acquisitions, consider investing in our cash-flow rich Personal Finance Growth portfolio stocks. Last week I discussed how Danone’s buyout offer for WhiteWave Foods was an example of the merger and acquisition activity that the Brexit vote will spawn as nervous executives in Europe look to buy… Read More
In the inaugural issue of Breakthrough Tech Profits, I recommended disk drive manufacturer Western Digital (WDC) as a play on growth in the SSD (solid state drive) market due to its recent acquisition of SanDisk. Although I felt the benefits from that transaction would be realized sooner than most… Read More
Juno Therapeutics (Nasdaq: JUNO), a company specializing in immunotherapy combined with chemotherapy and conventional cancer treatments, was rallying in early trading today, just five days after a massive 30 plus percent drop in price after two unexpected deaths occurred in a critical Phase II trial for end stage leukemia patients… Read More
All three of our cancer immunotherapy stocks made major announcements recently, but its still too soon to say which one will end up being the big winner. Read More
Juno Therapeutics (JUNO) announced this morning that it has halted its mid-stage trial study on JCAR015, a leukemia treatment that has resulted in the death of two participants in the study group. At this time there is not enough information available to determine the extent to which this development… Read More
While most investors have been fixated on the outcome of the Brexit vote over the past ten days, there was good news regarding a couple of the “Top Tech Takeover Targets” that I identified in our most recent issue of Breakthrough Tech Profits. Read More
In only one week the reaction to Britain’s vote to exit the European Union seems to have reversed course, swinging from shock to apathy. Despite dropping more than 5% in the two trading days immediately following the vote, the S&P 500 Index mostly recovered during the next three trading days… Read More
While the rest of the world was focused on the outcome of the “Brexit” vote last week, a couple of our Special Situations Portfolio stocks reported good news that may have been overlooked. Along with the overall decline in the stock market as a result of Great Britain’s decisions to… Read More
Despite its erratic trading behavior, thus far Argos has lived up to our expectations in terms of achieving its business objectives. And with an additional $30 million in cash to fund its operations, we see no reason to change our long term view on the company’s growth prospects. Read More